{"id":3973,"date":"2024-10-10T11:43:32","date_gmt":"2024-10-10T04:43:32","guid":{"rendered":"https:\/\/benhvienthaihoa.vn\/?p=3973"},"modified":"2025-06-22T22:44:48","modified_gmt":"2025-06-22T15:44:48","slug":"xet-nghiem-dong-mau-la-gi","status":"publish","type":"post","link":"https:\/\/benhvienthaihoa.vn\/en\/xet-nghiem-dong-mau-la-gi\/","title":{"rendered":"X\u00c9T NGHI\u1ec6M \u0110\u00d4NG M\u00c1U L\u00c0 G\u00cc?"},"content":{"rendered":"

1. X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u l\u00e0 g\u00ec? (What are Coagulation Tests?)<\/strong><\/p>\n

\u00a0– X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u l\u00e0 c\u00e1c x\u00e9t nghi\u1ec7m y khoa \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 kh\u1ea3 n\u0103ng \u0111\u00f4ng m\u00e1u c\u1ee7a m\u00e1u v\u00e0 \u0111\u1ec3 ph\u00e1t hi\u1ec7n c\u00e1c r\u1ed1i lo\u1ea1n li\u00ean quan \u0111\u1ebfn qu\u00e1 tr\u00ecnh n\u00e0y. C\u00e1c x\u00e9t nghi\u1ec7m n\u00e0y c\u00f3 th\u1ec3 gi\u00fap ch\u1ea9n \u0111o\u00e1n c\u00e1c t\u00ecnh tr\u1ea1ng b\u1ec7nh l\u00fd nh\u01b0 hemophilia, b\u1ec7nh Von Willebrand, v\u00e0 DIC (disseminated intravascular coagulation). Ngo\u00e0i ra, x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u c\u0169ng \u0111\u00f3ng vai tr\u00f2 quan tr\u1ecdng trong vi\u1ec7c theo d\u00f5i hi\u1ec7u qu\u1ea3 \u0111i\u1ec1u tr\u1ecb b\u1eb1ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng m\u00e1u (anticoagulant therapy).<\/span><\/p>\n

2.<\/strong> C\u00e1c lo\u1ea1i x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u ch\u00ednh (Key Types of Coagulation Tests)\"\"<\/b><\/p>\n

D\u01b0\u1edbi \u0111\u00e2y l\u00e0 c\u00e1c x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u ph\u1ed5 bi\u1ebfn nh\u1ea5t:<\/span><\/p>\n

a. Th\u1eddi gian prothrombin (Prothrombin Time – PT) v\u00e0 INR<\/b><\/p>\n

    \n
  1. PT<\/b>: \u0110o th\u1eddi gian m\u00e1u \u0111\u00f4ng qua con \u0111\u01b0\u1eddng ngo\u1ea1i sinh (extrinsic pathway) v\u00e0 con \u0111\u01b0\u1eddng chung (common pathway). X\u00e9t nghi\u1ec7m n\u00e0y th\u01b0\u1eddng \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 theo d\u00f5i t\u00e1c d\u1ee5ng c\u1ee7a thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng m\u00e1u nh\u01b0 warfarin.<\/span><\/li>\n
  2. INR<\/b>: L\u00e0 ch\u1ec9 s\u1ed1 chu\u1ea9n h\u00f3a qu\u1ed1c t\u1ebf \u0111\u1ec3 so s\u00e1nh k\u1ebft qu\u1ea3 x\u00e9t nghi\u1ec7m PT gi\u1eefa c\u00e1c ph\u00f2ng x\u00e9t nghi\u1ec7m kh\u00e1c nhau.\u00a0 <\/span><\/li>\n<\/ol>\n

    b. <\/strong>Th\u1eddi gian thromboplastin t\u1eebng ph\u1ea7n ho\u1ea1t h\u00f3a (Activated Partial Thromboplastin Time – aPTT)<\/b><\/p>\n

    aPTT \u0111o l\u01b0\u1eddng hi\u1ec7u qu\u1ea3 c\u1ee7a con \u0111\u01b0\u1eddng n\u1ed9i sinh (intrinsic pathway) v\u00e0 con \u0111\u01b0\u1eddng chung. X\u00e9t nghi\u1ec7m n\u00e0y th\u01b0\u1eddng \u0111\u01b0\u1ee3c d\u00f9ng \u0111\u1ec3 theo d\u00f5i hi\u1ec7u qu\u1ea3 c\u1ee7a heparin, m\u1ed9t lo\u1ea1i thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng \u0111\u01b0\u1ee3c d\u00f9ng r\u1ed9ng r\u00e3i trong \u0111i\u1ec1u tr\u1ecb b\u1ec7nh l\u00fd tim m\u1ea1ch v\u00e0 huy\u1ebft kh\u1ed1i.<\/span><\/p>\n

    c. Fibrinogen<\/b><\/p>\n

    Fibrinogen l\u00e0 m\u1ed9t y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u quan tr\u1ecdng, v\u00e0 m\u1ee9c \u0111\u1ed9 c\u1ee7a n\u00f3 c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn qu\u00e1 tr\u00ecnh h\u00ecnh th\u00e0nh c\u1ee5c m\u00e1u \u0111\u00f4ng. X\u00e9t nghi\u1ec7m fibrinogen gi\u00fap \u0111\u00e1nh gi\u00e1 nguy c\u01a1 ch\u1ea3y m\u00e1u v\u00e0 c\u00e1c r\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u nh\u01b0 DIC.<\/span><\/p>\n

    d. Th\u1eddi gian thrombin (Thrombin Time – TT)<\/b><\/p>\n

    Th\u1eddi gian thrombin \u0111o th\u1eddi gian \u0111\u1ec3 fibrinogen chuy\u1ec3n \u0111\u1ed5i th\u00e0nh fibrin khi thrombin \u0111\u01b0\u1ee3c th\u00eam v\u00e0o m\u00e1u. X\u00e9t nghi\u1ec7m n\u00e0y \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 ph\u00e1t hi\u1ec7n c\u00e1c b\u1ea5t th\u01b0\u1eddng v\u1ec1 fibrinogen ho\u1eb7c s\u1ef1 hi\u1ec7n di\u1ec7n c\u1ee7a c\u00e1c ch\u1ea5t \u1ee9c ch\u1ebf \u0111\u00f4ng m\u00e1u.<\/span><\/p>\n

    Tr\u00ean \u0111\u00e2y l\u00e0 nh\u1eefng x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u th\u01b0\u1eddng quy c\u00f3 th\u1ec3 th\u1ef1c hi\u1ec7n t\u1ea1i c\u00e1c ph\u00f2ng c\u01a1 s\u1edf y t\u1ebf c\u00f3 ph\u00f2ng XN. Hi\u1ec7n t\u1ea1i Ph\u00f2ng\u200a kh\u00e1m \u0110a khoa Th\u00e1i H\u00f2a ch\u00fang t\u00f4i \u0111ang th\u1ef1c hi\u1ec7n c\u00e1c k\u1ef9 thu\u1eadt n\u00e0y tr\u00ean m\u00e1y \u0111\u00f4ng m\u00e1u t\u1ef1 \u0111\u1ed9ng ACL TOP 350<\/span><\/p>\n

    \"\"<\/p>\n

    3. \u1ee8ng d\u1ee5ng l\u00e2m s\u00e0ng c\u1ee7a x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u (Clinical Applications of Coagulation Testing)<\/b><\/p>\n

    X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u c\u00f3 nhi\u1ec1u \u1ee9ng d\u1ee5ng l\u00e2m s\u00e0ng quan tr\u1ecdng, bao g\u1ed3m:<\/span><\/p>\n

      \n
    • Ch\u1ea9n \u0111o\u00e1n r\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u b\u1ea9m sinh<\/b>: C\u00e1c x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u gi\u00fap ph\u00e1t hi\u1ec7n c\u00e1c b\u1ec7nh l\u00fd di truy\u1ec1n nh\u01b0 hemophilia v\u00e0 b\u1ec7nh Von Willebrand.<\/span><\/li>\n
    • \u0110\u00e1nh gi\u00e1 tr\u01b0\u1edbc ph\u1eabu thu\u1eadt<\/b>: Tr\u01b0\u1edbc khi th\u1ef1c hi\u1ec7n c\u00e1c th\u1ee7 thu\u1eadt ph\u1eabu thu\u1eadt, x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o b\u1ec7nh nh\u00e2n kh\u00f4ng c\u00f3 nguy c\u01a1 cao b\u1ecb ch\u1ea3y m\u00e1u.<\/span><\/li>\n
    • Theo d\u00f5i \u0111i\u1ec1u tr\u1ecb b\u1eb1ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng<\/b>: B\u1ec7nh nh\u00e2n d\u00f9ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng nh\u01b0 warfarin v\u00e0 heparin c\u1ea7n \u0111\u01b0\u1ee3c theo d\u00f5i th\u01b0\u1eddng xuy\u00ean th\u00f4ng qua x\u00e9t nghi\u1ec7m PT, INR, v\u00e0 aPTT \u0111\u1ec3 \u0111i\u1ec1u ch\u1ec9nh li\u1ec1u thu\u1ed1c.<\/span><\/li>\n
    • Ch\u1ea9n \u0111o\u00e1n c\u00e1c b\u1ec7nh l\u00fd huy\u1ebft kh\u1ed1i v\u00e0 DIC<\/b>: X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u gi\u00fap ph\u00e1t hi\u1ec7n c\u00e1c t\u00ecnh tr\u1ea1ng huy\u1ebft kh\u1ed1i ho\u1eb7c r\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u nh\u01b0 DIC, \u0111\u1eb7c bi\u1ec7t trong c\u00e1c tr\u01b0\u1eddng h\u1ee3p c\u1ea5p c\u1ee9u ho\u1eb7c bi\u1ebfn ch\u1ee9ng sau ph\u1eabu thu\u1eadt.<\/span><\/li>\n<\/ul>\n

      X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u l\u00e0 ph\u01b0\u01a1ng ph\u00e1p kh\u00f4ng th\u1ec3 thi\u1ebfu trong ch\u1ea9n \u0111o\u00e1n v\u00e0 theo d\u00f5i nhi\u1ec1u b\u1ec7nh l\u00fd li\u00ean quan \u0111\u1ebfn \u0111\u00f4ng m\u00e1u. Hi\u1ec3u bi\u1ebft v\u1ec1 c\u00e1c x\u00e9t nghi\u1ec7m nh\u01b0 PT, aPTT, fibrinogen, v\u00e0 th\u1eddi gian thrombin gi\u00fap b\u00e1c s\u0129 l\u00e2m s\u00e0ng \u0111\u01b0a ra nh\u1eefng quy\u1ebft \u0111\u1ecbnh \u0111i\u1ec1u tr\u1ecb ch\u00ednh x\u00e1c, \u0111\u1eb7c bi\u1ec7t l\u00e0 trong c\u00e1c t\u00ecnh hu\u1ed1ng kh\u1ea9n c\u1ea5p v\u00e0 khi \u0111i\u1ec1u tr\u1ecb b\u1eb1ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng m\u00e1u. Tuy nhi\u00ean, vi\u1ec7c gi\u1ea3i th\u00edch k\u1ebft qu\u1ea3 x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u c\u1ea7n \u0111\u01b0\u1ee3c th\u1ef1c hi\u1ec7n th\u1eadn tr\u1ecdng, v\u00e0 \u0111\u00f4i khi c\u1ea7n k\u1ebft h\u1ee3p v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p ch\u1ea9n \u0111o\u00e1n kh\u00e1c \u0111\u1ec3 \u0111\u1ea1t \u0111\u01b0\u1ee3c \u0111\u1ed9 ch\u00ednh x\u00e1c cao nh\u1ea5t.<\/span><\/p>\n

      References \/ T\u00e0i li\u1ec7u tham kh\u1ea3o<\/b><\/p>\n

        \n
      1. Hoffbrand, A. V., & Moss, P. A. H. (2016). Hoffbrand’s Essential Haematology. John Wiley & Sons.<\/span><\/li>\n
      2. Mammen, E. F. (1992). Coagulation tests: A review. Seminars in Thrombosis and Hemostasis.<\/span><\/li>\n
      3. Tripodi, A. (2013). The Prothrombin Time Test as a Monitoring Tool for Oral Anticoagulation Therapy. Clinical Chemistry.<\/span><\/li>\n<\/ol>\n

        \u00a0 * T\u1ea1i sao b\u1ec7nh nh\u00e2n n\u00ean th\u1ef1c hi\u1ec7n x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u?<\/b><\/span><\/p>\n

          \n
        1. Ph\u00e1t hi\u1ec7n c\u00e1c r\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u (Detecting Blood Clotting Disorders)<\/b><\/li>\n<\/ol>\n

          X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u gi\u00fap ph\u00e1t hi\u1ec7n c\u00e1c r\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u m\u00e0 b\u1ec7nh nh\u00e2n c\u00f3 th\u1ec3 m\u1eafc ph\u1ea3i, d\u00f9 l\u00e0 r\u1ed1i lo\u1ea1n di truy\u1ec1n hay m\u1eafc ph\u1ea3i. M\u1ed9t s\u1ed1 b\u1ec7nh l\u00fd \u0111\u00f4ng m\u00e1u nh\u01b0 hemophilia, b\u1ec7nh Von Willebrand ho\u1eb7c t\u00ecnh tr\u1ea1ng thi\u1ebfu c\u00e1c y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u c\u00f3 th\u1ec3 khi\u1ebfn b\u1ec7nh nh\u00e2n c\u00f3 nguy c\u01a1 ch\u1ea3y m\u00e1u qu\u00e1 m\u1ee9c ho\u1eb7c b\u1ecb b\u1ea7m t\u00edm m\u00e0 kh\u00f4ng r\u00f5 nguy\u00ean nh\u00e2n. Ph\u00e1t hi\u1ec7n s\u1edbm c\u00e1c r\u1ed1i lo\u1ea1n n\u00e0y c\u00f3 th\u1ec3 gi\u00fap ng\u0103n ng\u1eeba c\u00e1c bi\u1ebfn ch\u1ee9ng nghi\u00eam tr\u1ecdng v\u00e0 \u0111\u01b0a ra k\u1ebf ho\u1ea1ch \u0111i\u1ec1u tr\u1ecb k\u1ecbp th\u1eddi.<\/span><\/p>\n

            \n
          1. Chu\u1ea9n b\u1ecb cho ph\u1eabu thu\u1eadt v\u00e0 c\u00e1c th\u1ee7 thu\u1eadt x\u00e2m l\u1ea5n (Preoperative and Invasive Procedure Preparation)\"\"<\/b><\/b><\/li>\n<\/ol>\n

            Tr\u01b0\u1edbc khi th\u1ef1c hi\u1ec7n ph\u1eabu thu\u1eadt ho\u1eb7c c\u00e1c th\u1ee7 thu\u1eadt x\u00e2m l\u1ea5n, vi\u1ec7c th\u1ef1c hi\u1ec7n x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u l\u00e0 v\u00f4 c\u00f9ng quan tr\u1ecdng. \u0110i\u1ec1u n\u00e0y gi\u00fap b\u00e1c s\u0129 \u0111\u00e1nh gi\u00e1 kh\u1ea3 n\u0103ng \u0111\u00f4ng m\u00e1u c\u1ee7a b\u1ec7nh nh\u00e2n v\u00e0 gi\u1ea3m thi\u1ec3u nguy c\u01a1 ch\u1ea3y m\u00e1u trong qu\u00e1 tr\u00ecnh ph\u1eabu thu\u1eadt. N\u1ebfu b\u1ec7nh nh\u00e2n c\u00f3 r\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u, b\u00e1c s\u0129 c\u00f3 th\u1ec3 \u0111i\u1ec1u ch\u1ec9nh ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb tr\u01b0\u1edbc ho\u1eb7c trong khi ph\u1eabu thu\u1eadt \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o an to\u00e0n.<\/span><\/p>\n

              \n
            1. Theo d\u00f5i v\u00e0 \u0111i\u1ec1u ch\u1ec9nh li\u1ec7u ph\u00e1p ch\u1ed1ng \u0111\u00f4ng m\u00e1u (Monitoring and Adjusting Anticoagulant Therapy)<\/b><\/li>\n<\/ol>\n

              B\u1ec7nh nh\u00e2n s\u1eed d\u1ee5ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng m\u00e1u nh\u01b0 warfarin, heparin, ho\u1eb7c c\u00e1c lo\u1ea1i thu\u1ed1c m\u1edbi nh\u01b0 rivaroxaban c\u1ea7n ph\u1ea3i \u0111\u01b0\u1ee3c theo d\u00f5i th\u01b0\u1eddng xuy\u00ean th\u00f4ng qua c\u00e1c x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u. \u0110i\u1ec1u n\u00e0y gi\u00fap \u0111\u1ea3m b\u1ea3o r\u1eb1ng li\u1ec1u l\u01b0\u1ee3ng thu\u1ed1c \u0111ang \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng l\u00e0 ph\u00f9 h\u1ee3p \u2013 \u0111\u1ee7 \u0111\u1ec3 ng\u0103n ng\u1eeba h\u00ecnh th\u00e0nh huy\u1ebft kh\u1ed1i, nh\u01b0ng kh\u00f4ng qu\u00e1 cao \u0111\u1ec3 tr\u00e1nh nguy c\u01a1 ch\u1ea3y m\u00e1u qu\u00e1 m\u1ee9c. X\u00e9t nghi\u1ec7m nh\u01b0 PT, INR v\u00e0 aPTT l\u00e0 c\u00f4ng c\u1ee5 quan tr\u1ecdng \u0111\u1ec3 \u0111i\u1ec1u ch\u1ec9nh li\u1ec1u thu\u1ed1c.<\/span><\/p>\n

                \n
              1. Ch\u1ea9n \u0111o\u00e1n v\u00e0 theo d\u00f5i c\u00e1c b\u1ec7nh l\u00fd huy\u1ebft kh\u1ed1i (Diagnosing and Monitoring Thrombotic Conditions)<\/b><\/li>\n<\/ol>\n

                X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u gi\u00fap ch\u1ea9n \u0111o\u00e1n v\u00e0 theo d\u00f5i c\u00e1c t\u00ecnh tr\u1ea1ng huy\u1ebft kh\u1ed1i, trong \u0111\u00f3 c\u00f3 huy\u1ebft kh\u1ed1i t\u0129nh m\u1ea1ch s\u00e2u (DVT) v\u00e0 thuy\u00ean t\u1eafc ph\u1ed5i (PE). C\u00e1c t\u00ecnh tr\u1ea1ng n\u00e0y c\u00f3 th\u1ec3 d\u1eabn \u0111\u1ebfn c\u00e1c bi\u1ebfn ch\u1ee9ng nghi\u00eam tr\u1ecdng n\u1ebfu kh\u00f4ng \u0111\u01b0\u1ee3c ph\u00e1t hi\u1ec7n v\u00e0 \u0111i\u1ec1u tr\u1ecb k\u1ecbp th\u1eddi. B\u1eb1ng c\u00e1ch th\u1ef1c hi\u1ec7n c\u00e1c x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u, b\u00e1c s\u0129 c\u00f3 th\u1ec3 x\u00e1c \u0111\u1ecbnh nguy c\u01a1 h\u00ecnh th\u00e0nh huy\u1ebft kh\u1ed1i v\u00e0 \u0111i\u1ec1u ch\u1ec9nh ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb.<\/span><\/p>\n

                  \n
                1. \u0110\u00e1nh gi\u00e1 t\u00ecnh tr\u1ea1ng s\u1ee9c kh\u1ecfe t\u1ed5ng qu\u00e1t (Assessing General Health Conditions)<\/b><\/li>\n<\/ol>\n

                  Trong m\u1ed9t s\u1ed1 tr\u01b0\u1eddng h\u1ee3p, c\u00e1c x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c y\u00eau c\u1ea7u nh\u01b0 m\u1ed9t ph\u1ea7n c\u1ee7a ki\u1ec3m tra s\u1ee9c kh\u1ecfe \u0111\u1ecbnh k\u1ef3 ho\u1eb7c \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 c\u00e1c t\u00ecnh tr\u1ea1ng b\u1ec7nh l\u00fd kh\u00e1c. V\u00ed d\u1ee5, b\u1ec7nh nh\u00e2n m\u1eafc b\u1ec7nh gan ho\u1eb7c b\u1ec7nh th\u1eadn th\u01b0\u1eddng c\u1ea7n ph\u1ea3i l\u00e0m x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u v\u00ec c\u00e1c c\u01a1 quan n\u00e0y \u0111\u00f3ng vai tr\u00f2 quan tr\u1ecdng trong vi\u1ec7c s\u1ea3n xu\u1ea5t c\u00e1c y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u v\u00e0 l\u1ecdc c\u00e1c ch\u1ea5t \u0111\u1ed9c h\u1ea1i trong m\u00e1u. N\u1ebfu ch\u1ee9c n\u0103ng gan ho\u1eb7c th\u1eadn b\u1ecb suy gi\u1ea3m, n\u00f3 c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn kh\u1ea3 n\u0103ng \u0111\u00f4ng m\u00e1u c\u1ee7a c\u01a1 th\u1ec3.<\/span><\/p>\n

                    \n
                  1. Ph\u00e1t hi\u1ec7n v\u00e0 \u0111i\u1ec1u tr\u1ecb t\u00ecnh tr\u1ea1ng \u0111\u00f4ng m\u00e1u n\u1ed9i m\u1ea1ch lan t\u1ecfa (Detecting and Managing Disseminated Intravascular Coagulation – DIC)<\/b><\/li>\n<\/ol>\n

                    T\u00ecnh tr\u1ea1ng \u0111\u00f4ng m\u00e1u n\u1ed9i m\u1ea1ch lan t\u1ecfa (DIC) l\u00e0 m\u1ed9t t\u00ecnh tr\u1ea1ng nghi\u00eam tr\u1ecdng trong \u0111\u00f3 h\u1ec7 th\u1ed1ng \u0111\u00f4ng m\u00e1u b\u1ecb k\u00edch ho\u1ea1t kh\u00f4ng ki\u1ec3m so\u00e1t, d\u1eabn \u0111\u1ebfn s\u1ef1 h\u00ecnh th\u00e0nh c\u1ee5c m\u00e1u \u0111\u00f4ng kh\u1eafp c\u01a1 th\u1ec3 v\u00e0 g\u00e2y ra ch\u1ea3y m\u00e1u qu\u00e1 m\u1ee9c. DIC th\u01b0\u1eddng l\u00e0 k\u1ebft qu\u1ea3 c\u1ee7a c\u00e1c t\u00ecnh tr\u1ea1ng b\u1ec7nh l\u00fd nghi\u00eam tr\u1ecdng nh\u01b0 nhi\u1ec5m tr\u00f9ng n\u1eb7ng, ung th\u01b0, ho\u1eb7c bi\u1ebfn ch\u1ee9ng thai k\u1ef3. X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u gi\u00fap ph\u00e1t hi\u1ec7n DIC k\u1ecbp th\u1eddi \u0111\u1ec3 can thi\u1ec7p v\u00e0 \u0111i\u1ec1u tr\u1ecb.<\/span><\/p>\n

                    K\u1ebft lu\u1eadn (Conclusion)<\/b><\/p>\n

                    X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u l\u00e0 m\u1ed9t c\u00f4ng c\u1ee5 quan tr\u1ecdng trong y h\u1ecdc, gi\u00fap ph\u00e1t hi\u1ec7n, ch\u1ea9n \u0111o\u00e1n v\u00e0 theo d\u00f5i nhi\u1ec1u b\u1ec7nh l\u00fd li\u00ean quan \u0111\u1ebfn \u0111\u00f4ng m\u00e1u. B\u1ec7nh nh\u00e2n n\u00ean th\u1ef1c hi\u1ec7n c\u00e1c x\u00e9t nghi\u1ec7m n\u00e0y \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o an to\u00e0n tr\u01b0\u1edbc khi ph\u1eabu thu\u1eadt, \u0111\u1ec3 theo d\u00f5i vi\u1ec7c s\u1eed d\u1ee5ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng, v\u00e0 \u0111\u1ec3 ph\u00e1t hi\u1ec7n s\u1edbm c\u00e1c r\u1ed1i lo\u1ea1n c\u00f3 th\u1ec3 g\u00e2y ra nguy c\u01a1 ch\u1ea3y m\u00e1u ho\u1eb7c h\u00ecnh th\u00e0nh c\u1ee5c m\u00e1u \u0111\u00f4ng. Vi\u1ec7c n\u00e0y gi\u00fap b\u00e1c s\u0129 \u0111\u01b0a ra c\u00e1c quy\u1ebft \u0111\u1ecbnh \u0111i\u1ec1u tr\u1ecb ph\u00f9 h\u1ee3p v\u00e0 c\u1ea3i thi\u1ec7n ch\u1ea5t l\u01b0\u1ee3ng cu\u1ed9c s\u1ed1ng c\u1ee7a b\u1ec7nh nh\u00e2n.<\/span><\/p>\n

                    \"\"* K\u1ebft qu\u1ea3 x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u n\u00f3i l\u00ean \u0111i\u1ec1u g\u00ec?<\/b><\/span><\/p>\n

                    K\u1ebft qu\u1ea3 c\u1ee7a x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u cung c\u1ea5p th\u00f4ng tin quan tr\u1ecdng v\u1ec1 kh\u1ea3 n\u0103ng \u0111\u00f4ng m\u00e1u c\u1ee7a b\u1ec7nh nh\u00e2n. D\u01b0\u1edbi \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec c\u00e1c k\u1ebft qu\u1ea3 x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u c\u00f3 th\u1ec3 ti\u1ebft l\u1ed9:<\/span><\/p>\n

                    1. K\u1ebft qu\u1ea3 th\u1eddi gian prothrombin (PT) v\u00e0 INR (Prothrombin Time and INR Results)<\/b><\/p>\n

                      \n
                    • PT b\u00ecnh th\u01b0\u1eddng<\/b>:\u00a0 Tr\u1ecb s\u1ed1 b\u00ecnh th\u01b0\u1eddng: 12s\u00a0 Th\u1eddi gian prothrombin b\u00ecnh th\u01b0\u1eddng cho th\u1ea5y qu\u00e1 tr\u00ecnh \u0111\u00f4ng m\u00e1u qua con \u0111\u01b0\u1eddng ngo\u1ea1i sinh (extrinsic pathway) v\u00e0 con \u0111\u01b0\u1eddng chung (common pathway) \u0111ang ho\u1ea1t \u0111\u1ed9ng b\u00ecnh th\u01b0\u1eddng. \u0110i\u1ec1u n\u00e0y ngh\u0129a l\u00e0 b\u1ec7nh nh\u00e2n kh\u00f4ng c\u00f3 d\u1ea5u hi\u1ec7u r\u1ed1i lo\u1ea1n v\u1ec1 c\u00e1c y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u li\u00ean quan \u0111\u1ebfn qu\u00e1 tr\u00ecnh n\u00e0y.<\/span><\/li>\n
                    • PT k\u00e9o d\u00e0i<\/b>: N\u1ebfu PT k\u00e9o d\u00e0i, \u0111i\u1ec1u n\u00e0y c\u00f3 th\u1ec3 cho th\u1ea5y m\u1ed9t s\u1ed1 v\u1ea5n \u0111\u1ec1 v\u1ec1 c\u00e1c y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u nh\u01b0 thi\u1ebfu h\u1ee5t c\u00e1c y\u1ebfu t\u1ed1 I (fibrinogen), II (prothrombin), V, VII, ho\u1eb7c X. N\u00f3 c\u0169ng c\u00f3 th\u1ec3 l\u00e0 d\u1ea5u hi\u1ec7u c\u1ee7a b\u1ec7nh gan, DIC, ho\u1eb7c t\u00e1c d\u1ee5ng c\u1ee7a thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng m\u00e1u nh\u01b0 warfarin.<\/span><\/li>\n
                    • INR<\/b>: INR l\u00e0 ch\u1ec9 s\u1ed1 chu\u1ea9n h\u00f3a gi\u00fap so s\u00e1nh k\u1ebft qu\u1ea3 PT gi\u1eefa c\u00e1c ph\u00f2ng x\u00e9t nghi\u1ec7m kh\u00e1c nhau. INR th\u01b0\u1eddng dao \u0111\u1ed9ng t\u1eeb 0.8 \u0111\u1ebfn 1.2 \u1edf ng\u01b0\u1eddi b\u00ecnh th\u01b0\u1eddng. \u1ede b\u1ec7nh nh\u00e2n d\u00f9ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng m\u00e1u, m\u1ee5c ti\u00eau INR c\u00f3 th\u1ec3 cao h\u01a1n, th\u01b0\u1eddng t\u1eeb 2.0 \u0111\u1ebfn 3.0 t\u00f9y v\u00e0o t\u00ecnh tr\u1ea1ng b\u1ec7nh l\u00fd c\u1ee5 th\u1ec3 (v\u00ed d\u1ee5, b\u1ec7nh nh\u00e2n rung nh\u0129 ho\u1eb7c \u0111\u1eb7t van tim nh\u00e2n t\u1ea1o).<\/span><\/li>\n<\/ul>\n
                        \n
                      1. K\u1ebft qu\u1ea3 th\u1eddi gian thromboplastin t\u1eebng ph\u1ea7n ho\u1ea1t h\u00f3a (aPTT Results)<\/b><\/li>\n<\/ol>\n
                          \n
                        • aPTT b\u00ecnh th\u01b0\u1eddng<\/b>:\u00a0 Tr\u1ecb s\u1ed1 b\u00ecnh th\u01b0\u1eddng 25.4 \u2013 36.9\u00a0 N\u1ebfu aPTT b\u00ecnh th\u01b0\u1eddng, \u0111i\u1ec1u \u0111\u00f3 cho th\u1ea5y con \u0111\u01b0\u1eddng n\u1ed9i sinh (intrinsic pathway) v\u00e0 con \u0111\u01b0\u1eddng chung \u0111ang ho\u1ea1t \u0111\u1ed9ng t\u1ed1t. \u0110i\u1ec1u n\u00e0y c\u00f3 ngh\u0129a l\u00e0 c\u00e1c y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u li\u00ean quan \u0111\u1ebfn hai con \u0111\u01b0\u1eddng n\u00e0y \u0111\u1ec1u \u1edf m\u1ee9c b\u00ecnh th\u01b0\u1eddng.<\/span><\/li>\n
                        • aPTT k\u00e9o d\u00e0i<\/b>: Th\u1eddi gian aPTT k\u00e9o d\u00e0i c\u00f3 th\u1ec3 ch\u1ec9 ra s\u1ef1 thi\u1ebfu h\u1ee5t ho\u1eb7c b\u1ea5t th\u01b0\u1eddng c\u1ee7a c\u00e1c y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u nh\u01b0 y\u1ebfu t\u1ed1 VIII, IX, XI, ho\u1eb7c XII. \u0110i\u1ec1u n\u00e0y th\u01b0\u1eddng g\u1eb7p trong c\u00e1c b\u1ec7nh l\u00fd nh\u01b0 hemophilia A (thi\u1ebfu y\u1ebfu t\u1ed1 VIII) ho\u1eb7c hemophilia B (thi\u1ebfu y\u1ebfu t\u1ed1 IX). Ngo\u00e0i ra, aPTT k\u00e9o d\u00e0i c\u0169ng c\u00f3 th\u1ec3 x\u1ea3y ra \u1edf b\u1ec7nh nh\u00e2n \u0111ang \u0111i\u1ec1u tr\u1ecb b\u1eb1ng heparin ho\u1eb7c c\u00f3 s\u1ef1 hi\u1ec7n di\u1ec7n c\u1ee7a kh\u00e1ng th\u1ec3 lupus ch\u1ed1ng \u0111\u00f4ng.<\/span><\/li>\n<\/ul>\n
                            \n
                          1. K\u1ebft qu\u1ea3 th\u1eddi gian thrombin (Thrombin Time – TT Results)<\/b><\/li>\n<\/ol>\n
                              \n
                            • Th\u1eddi gian thrombin b\u00ecnh th\u01b0\u1eddng<\/b>:\u00a0 Th\u1eddi gian b\u00ecnh th\u01b0\u1eddng 12\u2013 15s K\u1ebft qu\u1ea3 TT b\u00ecnh th\u01b0\u1eddng cho th\u1ea5y s\u1ef1 chuy\u1ec3n \u0111\u1ed5i t\u1eeb fibrinogen th\u00e0nh fibrin \u0111ang di\u1ec5n ra b\u00ecnh th\u01b0\u1eddng, kh\u00f4ng c\u00f3 b\u1ea5t th\u01b0\u1eddng v\u1ec1 fibrinogen ho\u1eb7c c\u00e1c ch\u1ea5t \u1ee9c ch\u1ebf qu\u00e1 tr\u00ecnh n\u00e0y.<\/span><\/li>\n
                            • Th\u1eddi gian thrombin k\u00e9o d\u00e0i<\/b>: N\u1ebfu TT k\u00e9o d\u00e0i, \u0111i\u1ec1u n\u00e0y c\u00f3 th\u1ec3 cho th\u1ea5y s\u1ef1 thi\u1ebfu h\u1ee5t fibrinogen ho\u1eb7c s\u1ef1 hi\u1ec7n di\u1ec7n c\u1ee7a c\u00e1c ch\u1ea5t \u1ee9c ch\u1ebf \u0111\u00f4ng m\u00e1u, ch\u1eb3ng h\u1ea1n nh\u01b0 c\u00e1c s\u1ea3n ph\u1ea9m ph\u00e2n h\u1ee7y fibrin (fibrin degradation products). N\u00f3 c\u0169ng c\u00f3 th\u1ec3 l\u00e0 d\u1ea5u hi\u1ec7u c\u1ee7a b\u1ec7nh gan n\u1eb7ng ho\u1eb7c DIC.<\/span><\/li>\n<\/ul>\n
                                \n
                              1. K\u1ebft qu\u1ea3 x\u00e9t nghi\u1ec7m fibrinogen (Fibrinogen Test Results)<\/b><\/li>\n<\/ol>\n
                                  \n
                                • Fibrinogen b\u00ecnh th\u01b0\u1eddng<\/b>:\u00a0 Tr\u1ecb s\u1ed1 b\u00ecnh th\u01b0\u1eddng: 238 \u00a0 \u2014\u00a0 498 mg\/dl m\u1ee9c fibrinogen b\u00ecnh th\u01b0\u1eddng cho th\u1ea5y y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u quan tr\u1ecdng n\u00e0y c\u00f3 m\u1eb7t \u0111\u1ea7y \u0111\u1ee7 \u0111\u1ec3 \u0111\u1ea3m b\u1ea3o s\u1ef1 h\u00ecnh th\u00e0nh c\u1ee5c m\u00e1u \u0111\u00f4ng khi c\u1ea7n thi\u1ebft.<\/span><\/li>\n
                                • Fibrinogen th\u1ea5p<\/b>: M\u1ee9c fibrinogen th\u1ea5p c\u00f3 th\u1ec3 l\u00e0 d\u1ea5u hi\u1ec7u c\u1ee7a DIC, b\u1ec7nh gan, ho\u1eb7c t\u00ecnh tr\u1ea1ng ti\u00eau th\u1ee5 fibrinogen qu\u00e1 m\u1ee9c trong qu\u00e1 tr\u00ecnh ch\u1ea3y m\u00e1u. Fibrinogen th\u1ea5p c\u0169ng c\u00f3 th\u1ec3 g\u1eb7p trong c\u00e1c t\u00ecnh tr\u1ea1ng vi\u00eam nhi\u1ec5m nghi\u00eam tr\u1ecdng ho\u1eb7c suy gi\u1ea3m ch\u1ee9c n\u0103ng gan.<\/span><\/li>\n
                                • Fibrinogen cao<\/b>: M\u1ee9c fibrinogen t\u0103ng cao c\u00f3 th\u1ec3 li\u00ean quan \u0111\u1ebfn t\u00ecnh tr\u1ea1ng vi\u00eam nhi\u1ec5m, ung th\u01b0, ho\u1eb7c c\u00e1c t\u00ecnh tr\u1ea1ng t\u0103ng \u0111\u00f4ng m\u00e1u, trong \u0111\u00f3 c\u01a1 th\u1ec3 t\u1ea1o ra qu\u00e1 nhi\u1ec1u y\u1ebfu t\u1ed1 \u0111\u00f4ng m\u00e1u.<\/span><\/li>\n<\/ul>\n
                                    \n
                                  1. \u00dd ngh\u0129a l\u00e2m s\u00e0ng t\u1ed5ng qu\u00e1t (General Clinical Significance)<\/b><\/li>\n<\/ol>\n

                                    C\u00e1c k\u1ebft qu\u1ea3 x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u cung c\u1ea5p th\u00f4ng tin quan tr\u1ecdng v\u1ec1 t\u00ecnh tr\u1ea1ng \u0111\u00f4ng m\u00e1u c\u1ee7a b\u1ec7nh nh\u00e2n v\u00e0 c\u00f3 th\u1ec3 ch\u1ec9 ra nhi\u1ec1u lo\u1ea1i r\u1ed1i lo\u1ea1n ho\u1eb7c b\u1ec7nh l\u00fd, bao g\u1ed3m:<\/span><\/p>\n

                                      \n
                                    • R\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u b\u1ea9m sinh<\/b>: K\u1ebft qu\u1ea3 c\u00f3 th\u1ec3 ph\u00e1t hi\u1ec7n c\u00e1c r\u1ed1i lo\u1ea1n di truy\u1ec1n nh\u01b0 hemophilia, b\u1ec7nh Von Willebrand, ho\u1eb7c thi\u1ebfu h\u1ee5t fibrinogen.<\/span><\/li>\n
                                    • R\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u m\u1eafc ph\u1ea3i<\/b>: B\u1ec7nh nh\u00e2n c\u00f3 th\u1ec3 m\u1eafc c\u00e1c b\u1ec7nh nh\u01b0 DIC, b\u1ec7nh gan, ho\u1eb7c s\u1eed d\u1ee5ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng m\u00e1u kh\u00f4ng ki\u1ec3m so\u00e1t. X\u00e9t nghi\u1ec7m gi\u00fap theo d\u00f5i v\u00e0 \u0111i\u1ec1u ch\u1ec9nh li\u1ec7u ph\u00e1p \u0111i\u1ec1u tr\u1ecb.<\/span><\/li>\n
                                    • Theo d\u00f5i hi\u1ec7u qu\u1ea3 \u0111i\u1ec1u tr\u1ecb<\/b>: \u0110\u1ed1i v\u1edbi b\u1ec7nh nh\u00e2n s\u1eed d\u1ee5ng thu\u1ed1c ch\u1ed1ng \u0111\u00f4ng m\u00e1u nh\u01b0 warfarin ho\u1eb7c heparin, k\u1ebft qu\u1ea3 x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u gi\u00fap \u0111\u1ea3m b\u1ea3o r\u1eb1ng li\u1ec1u l\u01b0\u1ee3ng thu\u1ed1c \u0111\u01b0\u1ee3c \u0111i\u1ec1u ch\u1ec9nh ph\u00f9 h\u1ee3p \u0111\u1ec3 ng\u0103n ng\u1eeba h\u00ecnh th\u00e0nh huy\u1ebft kh\u1ed1i m\u00e0 kh\u00f4ng g\u00e2y nguy c\u01a1 ch\u1ea3y m\u00e1u.<\/span><\/li>\n<\/ul>\n

                                      K\u1ebft qu\u1ea3 x\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u l\u00e0 ch\u1ec9 s\u1ed1 quan tr\u1ecdng trong vi\u1ec7c \u0111\u00e1nh gi\u00e1 t\u00ecnh tr\u1ea1ng s\u1ee9c kh\u1ecfe \u0111\u00f4ng m\u00e1u c\u1ee7a b\u1ec7nh nh\u00e2n. C\u00e1c k\u1ebft qu\u1ea3 n\u00e0y kh\u00f4ng ch\u1ec9 gi\u00fap ch\u1ea9n \u0111o\u00e1n c\u00e1c r\u1ed1i lo\u1ea1n \u0111\u00f4ng m\u00e1u m\u00e0 c\u00f2n h\u1ed7 tr\u1ee3 theo d\u00f5i hi\u1ec7u qu\u1ea3 c\u1ee7a li\u1ec7u ph\u00e1p ch\u1ed1ng \u0111\u00f4ng m\u00e1u. Vi\u1ec7c hi\u1ec3u r\u00f5 \u00fd ngh\u0129a c\u1ee7a t\u1eebng lo\u1ea1i x\u00e9t nghi\u1ec7m gi\u00fap b\u00e1c s\u0129 c\u00f3 c\u00e1i nh\u00ecn to\u00e0n di\u1ec7n v\u1ec1 t\u00ecnh tr\u1ea1ng c\u1ee7a b\u1ec7nh nh\u00e2n v\u00e0 \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh \u0111i\u1ec1u tr\u1ecb ch\u00ednh x\u00e1c.<\/span><\/p>","protected":false},"excerpt":{"rendered":"

                                      1. X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u l\u00e0 g\u00ec? (What are Coagulation Tests?) \u00a0– X\u00e9t nghi\u1ec7m \u0111\u00f4ng m\u00e1u l\u00e0 c\u00e1c x\u00e9t nghi\u1ec7m y khoa \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 kh\u1ea3 n\u0103ng \u0111\u00f4ng m\u00e1u c\u1ee7a m\u00e1u v\u00e0 \u0111\u1ec3 ph\u00e1t hi\u1ec7n c\u00e1c r\u1ed1i lo\u1ea1n li\u00ean quan \u0111\u1ebfn qu\u00e1 tr\u00ecnh n\u00e0y. C\u00e1c x\u00e9t nghi\u1ec7m n\u00e0y c\u00f3 th\u1ec3 gi\u00fap ch\u1ea9nLeer M\u00e1s<\/p>","protected":false},"author":1,"featured_media":3976,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[33],"tags":[],"class_list":["post-3973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-thong-tin-y-khoa"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/posts\/3973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/comments?post=3973"}],"version-history":[{"count":17,"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/posts\/3973\/revisions"}],"predecessor-version":[{"id":4292,"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/posts\/3973\/revisions\/4292"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/media\/3976"}],"wp:attachment":[{"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/media?parent=3973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/categories?post=3973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/benhvienthaihoa.vn\/en\/wp-json\/wp\/v2\/tags?post=3973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}